Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/075—Ethers or acetals
  • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

• the invention relates to tumor reducing compositions and methods of use thereof. Specifically, the invention relates to compositions comprising a combination of a sclerosing agent and a penetrating agent.
• Cancer can start almost anywhere in the body, but in all types, some of the body’s cells begin to divide without ceasing and spread into surrounding tissues. Normally, cells grow and divide to form new cells as the body needs them and when the cells grow old or become damaged, they die, with new cells taking their place. When cancer develops, however, this orderly process breaks down, so as cells become more and more abnormal, old or damaged cells survive when they should die, and new cells form when they are not needed. These extra cells can divide without stopping, thereby forming tumors. Many cancers form solid tumors, abnormal masses of tissue that result from this uncontrolled cell division or lack of orderly cell death.
• Cancerous tumors are malignant, meaning they can spread into, or invade, nearby tissues. In addition, as these tumors grow, some cancer cells can break off and travel to distant places in the body through the blood or the lymph system and form new tumors far from the original tumor.
• Tumors may also be benign (not cancerous) and although benign tumors do not spread into or invade surrounding tissues, some can be quite large and thus can also pose serious health problems and risks. Indeed, benign brain tumors can be life threatening.
• Cancer treatments today can include surgery, hormone therapy, radiation, chemotherapy, immunotherapy, and targeted therapy. Although progress continues to be made in the treatment of both benign and malignant tumors, each of these treatments has limitations and drawbacks, either in effectiveness, safety, or a combination. Many of these treatments are imprecise and at times, cancers can become resistent to them. Chemotherapeutic methods and radiation therapy can damage healthy tissue and cause numerous additional adverse effects, and surgical excision can be dangerous and ineffective when tumors grow large and become too invasive.
• a pharmaceutical composition comprising a combination of a sclerosing agent and a penetrating agent.
• the composition is a tumor reducing composition.
• the sclerosing agent is nonaethylene glycol monododecyl ether.
• the penetrating agent is anhydrous l-methyl-2-pyrrollidinone.
• the sclerosing agent and the penetrating agent are present in combination in an amount effective to reduce a size of a tumor in a subject.
• the subject is a mammal.
• the mammal is a human.
• the composition further comprises an alcohol.
• the alcohol is benzyl alcohol.
• the composition further comprises an acid.
• the acid is a bile acid.
• the bile acid is sodium deoxycholate.
• the composition further comprises a pain reducing agent.
• the pain reducing agent is lidocaine.
• the combination of sclerosing agent and penetrating agent present in the composition penetrates a tissue in presence of an acid.
• a pharmaceutical composition comprising benzyl alcohol, sodium deoxycholate, nonaethylene glycol monododecyl ether, and anhydrous 1- methyl-2-pyrrollidinone.
• compositions described herein are administered to the subject.
• a method of reducing a size of a tumor in a subject comprising contacting a tumor with a composition comprising a therapeutically effective amount of a combination of a sclerosing agent and a penetrating agent.
• a method of reducing a size of a tumor in a subject comprising contacting a tumor with a composition comprising a therapeutically effective amount of a combination of a sclerosing agent and a penetrating agent, and a bile acid.
• the contacting comprises intratumoral injection.
• the subject is a mammal.
• the mammal is a human.
• the tumor is a cancerous tumor.
• the tumor is present in a tissue of the breast, prostate, lung, colon, stomach, pancreas, ovary, brain, skin, bone, fat, lymph, gastrointestinal tract, liver, or soft tissue.
• the composition further comprises an alcohol.
• the alcohol is benzyl alcohol.
• the composition further comprises an acid.
• the acid is a bile acid.
• the bile acid is sodium deoxycholate.
• the composition further comprises a pain reducing agent.
• the pain reducing agent is lidocaine.
• the combination of sclerosing agent and penetrating agent present in the composition penetrates a tissue in presence of an acid.
• the composition comprises benzyl alcohol, sodium deoxycholate, nonaethylene glycol monododecyl ether, and anhydrous l-methyl-2-pyrrollidinone.
• tumor size of the tumor contacted with the composition is reduced by about 25% to about 100% compared to a reduction of tumor size of a tumor contacted with a control.
• the tumor contacted with the composition comprises an increase in intratumoral necrosis compared to a tumor contacted with a control.
• the control comprises bacteriostatic water.
• a method of treating a lesion in a subject comprising contacting the lesion with any of the pharmaceutical compositions as described herein.
• the lesion is present in a tissue of the breast, prostate, lung, colon, stomach, pancreas, ovary, brain, skin, bone, fat, lymph, gastrointestinal tract, liver, or soft tissue.
• the lesion is noncancerous.
• reducing or decreasing the size of a tumor can include reducing size as measured by volume, weight, cell number, decrease in number of living cells, increase in necrosis, or any other method for measuring size, or slowing or halting of, or reduction in growth.
• volume of tumor size is calculated as length x width x width x 0.52.
• tumor size is decreased by between about 1% and about 100%.
• tumor size is decreased by between about 25% and about 50%.
• tumor size is decreased by about 50%, about 55%, about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99% or about 100%.
• tumor size is decreased by 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100%.
• the terms“treat”,“treatment”, or“therapy” refer to therapeutic treatment, including prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change associated with a disease or condition.
• Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of the extent of a disease or condition, stabilization of a disease or condition (i.e., where the disease or condition does not worsen), delay or slowing of the progression of a disease or condition, amelioration or palliation of the disease or condition, and remission (whether partial or total) of the disease or condition, whether detectable or undetectable.
• Those in need of treatment include those already with the disease or condition as well as those prone to having the disease or condition or those in which the disease or condition is to be prevented.
• composition As used herein, the terms “component,” “composition,”“formulation”, “composition of compounds,” “compound,” “drug,” “pharmacologically active agent,” “active agent,” “therapeutic,” “therapy,” “treatment,” or “medicament” are used interchangeably herein, as context dictates, to refer to a compound or compounds or composition of matter which, when administered to a subject (human or animal) induces a desired pharmacological and/or physiologic effect by local and/or systemic action.
• subject refers to an animal, for example a human, to whom treatment with a pharmaceutical composition in accordance with the present invention, is provided.
• subject refers to human and non-human animals.
• non-human animals and “non-human mammals” are used interchangeably herein and include all vertebrates, e.g., mammals, such as non-human primates, (particularly higher primates), sheep, dog, rodent, (e.g. mouse or rat), guinea pig, goat, pig, cat, rabbits, cows, horses and non -mammals such as reptiles, amphibians, chickens, and turkeys.
• the formulations described herein can be used to treat any suitable mammal, including primates, such as monkeys and humans, horses, cows, cats, dogs, rabbits, and rodents such as rats and mice.
• the mammal to be treated is human.
• the human can be any human of any age. In an embodiment, the human is an adult. In another embodiment, the human is a child. According to any of the methods of the present invention and in one embodiment, the subject is human. In another embodiment, the subject is a non human primate.
• the subject is murine, which in one embodiment is a mouse, and, in another embodiment is a rat.
• the subject is canine, feline, bovine, equine, laprine or porcine.
• the subject is mammalian ⁇ In another embodiment, the subject is any organism susceptible to cancer or tumors.
• Conditions and disorders in a subject for which a particular drug or compound or composition (or combination thereof) is said herein to be “indicated” are not restricted to conditions and disorders for which that drug or compound or composition has been expressly approved by a regulatory authority, but also include other conditions and disorders known or reasonably believed by a physician to be amenable to treatment with that drug or compound or composition or combination thereof.
• compositions and methods described herein contemplate treating tumors, including reducing their size.
• Tumor has the meaning ordinarily understood in the art, and includes an abnormal mass of tissue, typically resulting when cells divide more than they should or do not die when they should.
• Tuors as referred to herein may be benign (not cancerous), or malignant (cancerous) and may occur any place in the body.
• “Lesion” as used herein refers to any abnormal area of tissue and can include, without limitation, benign and malignant tumors.
• the compositions, formulations, and methods for reducing tumor size described herein comprise sclerosing agents.
• Sclerosing agents act frequently by irritation of the venous intimal, or innermost, epithelium and are typically used in the treatment of varicose veins. More specifically, sclerosing agents cause a marked irritation or thrombosis with subsequent local inflammation and tissue necrosis and tissue contraction.
• the sclerosing agent, or sclerosant is injected into a vein to entirely obliterate it. The agent damages the innermost lining of the vessel (the endothelium), resulting in a clot that blocks the blood circulation in the vein beyond, or creating scar tissue.
• the sclerosing agent comprises nonaethylene glycol monododecyl ether.
• Nonaethylene glycol monododecyl ether is readily available and also can be referred to as C12E9, Dodecyl nonaethylene glycol ether, Dodecylnonaglycol, Polidocanol,
• the nonaethylene glycol monododecyl ether is 98% nonaethylene glycol monododecyl ether. In embodiments, compositions in accordance with the present invention comprise about 1% of 98% nonaethylene glycol monododecyl ether by volume. In other embodiments, compositions in accordance with the present invention comprise 1% of 98% nonaethylene glycol monododecyl ether by volume.
• sclerosing agents known in the art can also be employed in the compositions and methods described herein, including, without limitation, Laureth-9 (polidocanol), ethanolamine oleate, morrhuate sodium, sodium tetradecyl sulfate, sterile talc powder, other suitable detergents, osmotic agents such as hypertonic sodium chloride solution and sodium chloride solution with dextrose, or chemical irritants, such as chromated glycerin and polyiodinated iodine, sclerosant foam formulations, alcohol, or other suitable sclerosing agents or derivatives, and combinations thereof.
• Laureth-9 polidocanol
• morrhuate sodium sodium tetradecyl sulfate
• sterile talc powder other suitable detergents
• osmotic agents such as hypertonic sodium chloride solution and sodium chloride solution with dextrose
• chemical irritants such as chromated gly
• compositions, formulations, and methods described herein comprise a penetrating agent.
• Penetrating agents also referred to herein as permeation enhancers, penetration enhancers, sorption promoters or accelerants, penetrate into skin to reversibly decrease the barrier resistance.
• the penetrating agent comprises l-methyl-2-pyrrolidinone.
• the l-methyl-2-pyrrolidinone is anhydrous l-methyl-2-pyrrolidinone.
• the l-methyl-2-pyrrolidinone is 99.5% anhydrous l-methyl-2-pyrrolidinone.
• 1- methyl-2-pyrrolidinone is readily available and is also referred to as l-Methyl-2-pyrrolidone or N-Methyl-2-pyrrolidone. Its Empirical Formula (Hill Notation) is C 5 H 9 NO and its chemical structure can be depicted as:
• compositions and methods in accordance with the present invention comprise about 0.1% of 99.5% anhydrous l-methyl-2-pyrrolidinone. In embodiments, compositions and methods in accordance with the present invention comprise 0.1% of 99.5% anhydrous 1 -methyl-2-pyrrolidinone.
• Such compounds suitable as penetrating agents in accordance with the compositions, formulations, and methods described herein include, without limitation, solvents, sulfoxides, Azones (e.g. laurocapram), other pyrrolidones (for example 2-pyrrolidone, 2P), alcohols and alkanols (e.g. ethanol, or decanol), glycols (for example propylene glycol, PG, a common excipient in topically applied dosage forms), surfactants (also common in dosage forms) and terpenes.
• solvents e.g. laurocapram
• other pyrrolidones for example 2-pyrrolidone, 2P
• alcohols and alkanols e.g. ethanol, or decanol
• glycols for example propylene glycol, PG, a common excipient in topically applied dosage forms
• surfactants also common in dosage forms
• examples of the above and other penetrating agents suitable for use in accordance with the compositions and methods described herein include, without limitation, water, hydrocarbons, such as alkanes, alkenes, halogenated alkanes, squalene, squalene, and mineral oil; alcohols, such as alkanols, alkenols, glycols, polyglycols, and glyerols; acids, such as fatty acids, amines, cyclic and acyclic amides, such as azone and pyrrolidones, esters, such as isopropyl myristate, surfactants, including anionic, cationic, zwitterionic and non-ionic surfactants; terpenes, terpenoids, and essential oils; sulfoxides, such as dimethyl sulfoxide (DMSO) and its derivatives; lipids, such as phospholipids, and various other chemical groups, such as cyclic oligo
• tumor penetrating peptides include tumor penetrating peptides, cell-penetrating peptides, and other suitable compounds and agents capable of penetrating skin, tissue and/or cell membranes.
• suitable compounds and agents capable of penetrating skin, tissue and/or cell membranes.
• compositions, formulations, and methods described herein comprise an acid (or salt thereof) and/or include methods wherein target tissue, such as that comprising a tumor contacted with a composition as described herein, comprises an acid (or salt thereof).
• target tissue such as that comprising a tumor contacted with a composition as described herein
• an acid or salt thereof
• the term“acid” has a meaning in accordance with any of those commonly understood by one of ordinary skill in the art.
• An acid therefore includes, without limitation, a chemical substance whose aqueous solutions are characterized by a sour taste, the ability to turn blue litmus red, or the ability to react with bases and certain metals (like calcium) to form salts.
• acid salts including pharmaceutically acceptable salts, are also contemplated and within the scope of the invention.
• Aqueous solutions of acids have a pH of less than 7.
• acids suitable for use in accordance with the present invention include acids falling under the Lewis definition of an acid, i.e., a substance that can accept a pair of electrons to form a covalent bond, the Arrhenius Definition of an acid, i.e., substances which increase the concentration of hydrogen ions (H+), or hydronium ions (H3O+), when dissolved in water, and the expansive Bronsted- Lowry Definition of an acid, i.e., a substance that can act a proton donor, and thus, any compound that can easily be deprotonated can be considered an acid.
• An acid suitable for use in the invention and/or found naturally in tissue therefore includes, without limitation, hydrochloric acid, lactic acid, a bile acid (including e.g., deoxycholic acid (deoxycholate), cholic acid, glycocholic acid, taurocholic acid, chenodeoxycholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, lithocholic acid), nucleic acids, fatty acids and fatty acid derivatives, amino acids, gastric acid, hyaluronic acid, ascorbic acid (Vitamin C), Bronsted and Lewis acids, carboxylic acids, halogenated carboxylic acids, acetylsalicylic acids, salicylic acids and variants and derivatives and salts thereof.
• hydrochloric acid including e.g., deoxycholic acid (deoxycholate), cholic acid, glycocholic acid, taurocholic acid, chenodeoxycholic acid, glycochenodeoxycholic acid, taurocheno
• Bile Acids known in the art and suitable for use in the compositions and methods described herein and/or present in tissue comprising a tumor contacted by compositions and in methods in accordance with those described herein, include steroid acids found predominantly in the bile of mammals and other vertebrates.
• Bile acids are conjugated with taurine or glycine in the liver, and the sodium and potassium salts of these conjugated bile acids are referred to as bile salts.
• bile salts The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72: 137— 74; Chiang JY (October 2009).
• Bile acids regulation of synthesis. J. Lipid Res. 50 (10): 1955-66. Carey, MC.; Small, DM. (Oct 1972).
• Mericelle formation by bile salts Physical- chemical and thermodynamic considerations. Arch Intern Med. 130 (4): 506-27.
• Bile acids are about 80% of the organic compounds in bile (others are phospholipids and cholesterol). An increased secretion of bile acids produces an increase in bile flow.
• the main function of bile acids is to allow digestion of dietary fats and oils by acting as a surfactant that emulsifies them into micelles, allowing them to be colloidally suspended in the chyme before further processing. (See Hofmann AF, Borgstrom B (February 1964). "The intraluminal phase of fat digestion in man: the lipid content of the micellar and oil phases of intestinal content obtained during fat digestion and absorption". J. Clin. Invest.
• Bile acids and colon cancer may have some importance in the development of colorectal cancer.
• DC A Deoxycholic acid
• DC A Deoxycholic acid
• the compositions, formulations, and methods of the present invention comprise an acid.
• the acid comprises a bile acid.
• the bile acid comprises deoxycholate or a salt thereof.
• the composition comprises about 3% Na deoxycholate by weight.
• the composition comprises 3% Na deoxycholate by weight.
• the Na is dissolved in an alcohol.
• the alcohol comprises benzyl alcohol.
• the benzyl alcohol comprises about 3% benzyl alcohol, by volume.
• the benzyl alcohol comprises 3% benzyl alcohol by volume.
• any other suitable acid including other suitable bile acids, can be employed in acccordance with the present invention.
• compositions, formulations, and methods described herein comprise an alcohol.
• Alcohols include any organic compound in which the hydroxyl functional group (-OH) is bound to a carbon atom of an alkyl group.
• the alcohol comprises benzyl alcohol.
• the benzyl alcohol comprises about 3% benzyl alcohol by volume. In an embodiment, the benzyl alcohol comprises 3% benzyl alcohol, by volume.
• Any other suitable alcohol can also be employed, including, without limitation any primary, secondary, or tertiary alcohol, any alkanol, alkenol, or any aromatic alcohol, any linear of branched alcohols of any size or chain length, any saturated or unsaturated alcohol, or any other compound that falls within the broad range of alcohols as understood by one of ordinary skill in the art.
• alcohols in addition to benzyl alcohol suitable for use in the compositions, formulations, and methods described herein include, without limitation, linear alcohols such as methanol, ethanol, propanol, butanol, pentanol, hexanol, octanol, nonanol, decanol, or any other of any chain length that is known and readily available, other aromatic alcohols such as, without limitation, tryptophol, tyrosol, and phenylethanol, or any other suitable alcohol.
• linear alcohols such as methanol, ethanol, propanol, butanol, pentanol, hexanol, octanol, nonanol, decanol, or any other of any chain length that is known and readily available
• other aromatic alcohols such as, without limitation, tryptophol, tyrosol, and phenylethanol, or any other suitable alcohol.
• the compositions, formulations, and methods described herein can comprise the inclusion or use of a pain-reducing agent in an amount effective to reduce pain in the subject.
• the pain reducing agent comprises a general anesthetic.
• the pain reducing agent comprises a local anesthetic.
• the pain reducing agent comprises lidocaine.
• the composition comprises about 1% of 2% lidocaine.
• the composition comprises 1% of 2% lidocaine.
• the pain reducing agent can be present in any preparation suitable for use in accordance with the compositions and methods described herein, including, without limitation, a 0.5%, 1%, 1.5%, 2%, 4%, or 5% injectable solution; or a 200, 400, or 800 mg/mL preparation.
• the composition comprises between about 0.1% and about 1% of a pain reducing agent. In an embodiment, the composition comprises between about 1% and about 10% of a pain reducing agent.
• the pain reducing agent is comprised within the tumor reducing composition. In an embodiment, the pain reducing agent is administered separately from the tumor reducing composition.
• Suitable pain reducing agents for use in accordance with the present invention include, without limitation, procaine, bupivacaine, mepivacine, chloroprocine, tetracaine, ropivacaine, benzocaine, or any other suitable pain reducing agent known to one of ordinary skill in the art.
• compositions comprising compounds of the invention and one or more pharmaceutically acceptable carriers.
• “Pharmaceutically acceptable carriers” include any excipient which is nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed.
• the pharmaceutical composition may include one or more therapeutic agents.
• pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration ⁇ Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
• “Pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
• pharmaceutically acceptable also includes those carriers approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals and, more particularly, in humans.
• compositions containing the therapeutic agent or agents described herein can be, in one embodiment, administered to a subject by any method known to a person skilled in the art, such as, without limitation, parenterally, transmucosally, subcutaneously, intramuscularly, intravenously, intraarterially, intra-peritonealy, intra- cranially, intra-vaginally, or intra-tumorally.
• the therapeutic agent or combination of therapeutic agents is administered intra-tumorally.
• Carriers may be any of those conventionally used, as described above, and are limited only by chemical-physical considerations, such as solubility and lack of reactivity with the compound of the invention, and by the route of administration ⁇
• suitable carriers include lactose, glucose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water and methylcellulose.
• the formulations can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents, surfactants, emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; flavoring agents, colorants, buffering agents (e.g., acetates, citrates or phosphates), disintegrating agents, moistening agents, antibacterial agents, antioxidants (e.g., ascorbic acid or sodium bisulfite), chelating agents (e.g., ethylenediaminetetraacetic acid), and agents for the adjustment of tonicity such as sodium chloride.
• lubricating agents such as talc, magnesium stearate, and mineral oil
• wetting agents such as surfactants, emulsifying and suspending agents
• preserving agents such as methyl- and propylhydroxybenzoates
• sweetening agents e.g., acetates, citrates or phosphates
• Other pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents.
• water preferably bacteriostatic water, is the carrier when the pharmaceutical composition is administered intravenously or intratumorally.
• Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
• compositions suitable for injectable use may include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
• suitable carriers include, without limitation, physiological saline, bacteriostatic water, Cremophor EL.TM. (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
• the composition should be sterile and should be fluid to the extent that easy syringeability exists. It should be stable under the conditions of manufacture and storage and be preserved against the contaminating action of microorganisms such as bacteria and fungi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
• the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
• Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
• Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as appropriate, followed by filtered sterilization.
• dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
• methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
• the disclosed compounds may be prepared in the form of pharmaceutically acceptable salts.
• “Pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
• Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
• such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
• inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
• organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
• physiologically acceptable salts are prepared by methods known in the art, e.g., by dissolving the free amine bases with an excess of the acid in aqueous alcohol, or neutralizing a free carboxylic acid with an alkali metal base such as a hydroxide, or with an amine.
• Common salt-forming cations include, without limitation, ammonium, calcium, iron, magnesium, potassium, pyridinium, quaternary ammonium, sodium, and copper.
• Common salt-forming anions include, without limitation, acetate, carbonate, chloride, citrate, cyanide, fluoride, nitrate, nitrite, oxide, phosphate, and sulfate.
• Compounds described herein also can be prepared in alternate forms. For example, many amino-containing compounds can be used or prepared as an acid addition salt. Often such salts improve isolation and handling properties of the compound. For example, depending on the reagents, reaction conditions and the like, compounds as described herein can be used or prepared, for example, as their hydrochloride or tosylate salts. Isomorphic crystalline forms, all chiral and racemic forms, N-oxide, hydrates, solvates, and acid salt hydrates, are also contemplated to be within the scope of the present invention.
• Certain acidic or basic compounds of the present invention may exist as zwitterions. All forms of the compounds, including free acid, free base and zwitterions, are contemplated to be within the scope of the present invention. It is well known in the art that compounds containing both amino and carboxy groups often exist in equilibrium with their zwitterionic forms. Thus, any of the compounds described herein that contain, for example, both amino and carboxy groups, also include reference to their corresponding zwitterions.
• compositions and formulations as described herein may be administered alone or with other biologically-active agents. Administration can be systemic or local, e.g. through portal vein delivery to the liver.
• compositions are formulated in a unit dosage form.
• unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
• a pharmaceutical composition of the invention may be administered locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material.
• administration can be by direct injection e.g., via a syringe, at the site of a tumor or neoplastic or pre-neoplastic tissue.
• a compound of the present invention can be delivered in an immediate release or in a controlled release system.
• an infusion pump may be used to administer a compound of the invention, such as one that is used for delivering chemotherapy to specific organs or tumors (see Buchwald et al., 1980, Surgery 88: 507; Saudek et ak, 1989, N. Engl. J. Med. 321: 574).
• a compound of the invention is administered in combination with a biodegradable, biocompatible polymeric implant, which releases the compound over a controlled period of time at a selected site.
• polymeric materials include poly anhydrides, poly orthoesters, polyglycolic acid, polylactic acid, polyethylene vinyl acetate, copolymers and blends thereof (See, Medical applications of controlled release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla.).
• a controlled release system can be placed in proximity of the therapeutic target, thus requiring only a fraction of the systemic dose.
• the pharmaceutical compositions formulated for parenteral administration may include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Oils such as petroleum, animal, vegetable, or synthetic oils and soaps such as fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents may also be used for parenteral administration. The above formulations may also be used for direct intra- tumoral injection.
• compositions may contain one or more nonionic surfactants.
• Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
• a pain reducing agent as described herein, also may be administered either within the formulation, or separate from it.
• parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use.
• sterile liquid carrier for example, water
• Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described and known in the art.
• Effective doses of the compositions of the present invention, for treatment of conditions or diseases vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic.
• the patient is a human, but non-human mammals including transgenic mammals can also be treated.
• Treatment dosages may be titrated using routine methods known to those of skill in the art to optimize safety and efficacy.
• the pharmaceutical compositions of the invention thus may include a“therapeutically effective amount.”
• A“therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
• a therapeutically effective amount of a molecule may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the molecule to elicit a desired response in the individual.
• a therapeutically effective amount is also one in which any toxic or detrimental effects of the molecule are outweighed by the therapeutically beneficial effects.
• the term "therapeutically effective amount” may encompass total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
• a meaningful patient benefit i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
• the term refers to that ingredient alone.
• the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
• in vitro assays may optionally be employed to help identify optimal dosage ranges.
• the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances.
• the dosage will be within the range of 0.01-1000 mg/kg of body weight.
• the dosage will be within the range of 0.1 mg/kg to 100 mg/kg.
• the dosage will be within the range of 1 mg/kg to 10 mg/kg.
• Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test bioassays or systems.
• suitable doses may also be influenced by permissible daily exposure limits (PDE) of any compound included in a formulation or method as described herein.
• PDE permissible daily exposure limits
• Such limits are readily available, including, for example, from industry guidance recommendations provided periodically from the U.S. Food and Drug Administration, and the evaluation of these limits are within the knowledge and understanding of one of ordinary skill in the art.
• administering refers to bringing in contact with a compound of the present invention. Administration can be accomplished to cells or tissue cultures, or to living organisms, for example humans. In one embodiment, the present invention encompasses administering the compounds and compositions of the present invention to a human subject.
• methods of the present invention comprise the step of contacting one or more cells of said subject with a compound or a composition as described herein.
• contacting one or more cells of a subject with a compound described herein comprises the step of administering a composition comprising said compound to said subject.
• the administration of a sclerosing agent and a penetrating agent, in accordance with the invention as described herein, may occur either simultaneously or time- staggered, either at the same site of administration or at different sites of administration ⁇
• a timepoint comprises a point in time. In another embodiment, a timepoint comprises a time period shorter than 1 minute. In another embodiment, a timepoint comprises a time period shorter than 5 minutes. In another embodiment, a timepoint comprises a time period shorter than 30 minutes.
• a timepoint comprises a time period shorter than 1 minute.
• any of the therapeutic or prophylactic drugs or compounds described herein may be administered simultaneously. In another embodiment, they may be administered at different timepoint than one another. In one embodiment, they may be administered within a few minutes of one another. In another embodiment, they may be administered within a few hours of one another. In another embodiment, they may be administered within 1 hour of one another. In another embodiment, they may be administered within 2 hours of one another. In another embodiment, they may be administered within 5 hours of one another. In another embodiment, they may be administered within 12 of one another. In another embodiment, they may be administered within 24 hours of one another.
• any of the therapeutic or prophylactic drugs or compounds described herein may be administered at the same site of administration. In another embodiment, they may be administered at different sites of administration.
• composition of the invention may be administered only once, or it may be administered multiple times.
• the composition may be, for example, administered three times a day, twice a day, once a day, once every two days, twice a week, weekly, once every two weeks, or monthly. Suitable dosage ranges and schedules can vary.
• a tumor in a subject is intratumorally injected on about day 1 and about day 3, on about day 8 and about day 10, on about day 15 and about day 17, on about day 22 and about day 24, on about day 29 and about day 31, and on about day 36.
• dosing volume comprises about 50 ul of the composition per tumor during week one. In an embodiment, dosing volume comprises about 100 ul of the composition per tumor for week two. In an embodiment, dosing volume comprises about 200 ul of the composition for the remainder of the dosing administrations. In embodiments, dosing volume of the composition can range from about 5 ul to about 2000 ul of the composition per tumor.
• dosing volumes can range from about 5 ul to about 500 ul of the composition per tumor. In embodiments, dosing volume of the composition can range from about 10 ul to about 1000 ul of the composition per tumor. In embodiments, dosing volume of the composition can range from about 20 ul to about 2000 ul of the composition per tumor.
• dosing volume comprises 50 ul of the composition per tumor during week one, 100 ul of the composition per tumor for week two, and 200 ul of the composition for the remainder of the dosing administrations ⁇ In an embodiment, dosing volume comprises 50 ul of the composition administered on day 1 and day 3, 100 ul of the composition per tumor administered on day 8 and day 10, and 200 ul of the composition administered on day 15, day 17, day 22, day 24, day 29, day 31, and day 36. (See Example 1). Determining other suitable dosing schedules and composition dosage ranges and amounts are within the skill of the ordinary artisan.
• the tumor reducing compostion described herein comprises about 3% alcohol by volume, about 3% of an acid by weight (dissolved in the alcohol), about 1% of sclerosing agent by volume, about 0.1% penetrating agent, and QS bacteriostatic water.
• the tumor reducing compostion described herein comprises about 3% benzyl alcohol by volume, about 3% Na deoxycholate by weight (dissolved in the alcohol), about 1% of 98% nonaethylene glycol monododecyl ether by volume, about 0.1% of 99.5% anhydrous l-methyl-2-pyrrolidinone, and QS bacteriostatic water.
• the tumor reducing composition described herein comprises 3% benzyl alcohol by volume, 3% Na deoxycholate by weight (dissolved in the alcohol), 1% of 98% nonaethylene glycol monododecyl ether by volume, 0.1% of 99.5% anhydrous l-methyl-2-pyrrolidinone, and QS bacteriostatic water.
• the alcohol can be present in an amount between about 0.3% and about 30% by volume.
• the acid can be present in an amount between about 0.3% and about 30% by volume.
• the sclerosing agent can be present in an amount between about 0.1% and about 10% by volume.
• the penetrating agent can be present in an amount between about .01% and about 1%.
• dosage values and amounts and ratios of individual components of the compositions described herein also may vary with the type and severity of the condition to be alleviated and other factors. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
• compositions described and contemplated herein can be included in a container, pack, or dispenser together with instructions for administration.
• compositions and methods described herein contemplate treatment of lesions, tumors, or tumor cells located in any tissue in which such lesions or tumors can occur in a subject.
• the compositions and methods described herein are suitable for use in disaggregating or removing any tissue to which the composition is applied and for which such result is desired.
• the methods of the present invention comprise inhibiting proliferation of cancer or tumor cells.
• inhibiting proliferation in relation to cancer cells, in the context of the present invention refers to a decrease in at least one of the following: number of cells (due to cell death which may be necrotic, apoptotic or any other type of cell death or combinations thereof) as compared to control; decrease in growth rates of cells, i.e.
• the total number of cells may increase but at a lower level or at a lower rate than the increase in control; decrease in the invasiveness of cells (as determined for example by soft agar assay) as compared to control even if their total number has not changed; progression from a less differentiated cell type to a more differentiated cell type; a deceleration in the neoplastic transformation; or alternatively the slowing of the progression of the cancer cells from one stage to the next.
• treatment of cancer or“treatment of a tumor” or“reducing size of a tumor” in the context of the present invention also includes at least one of the following: a decrease in the rate of growth of the cancer or tumor (i.e. the cancer or tumor still grows but at a slower rate); cessation of growth of the cancerous growth, i.e., stasis of the tumor growth, and, in one embodiment, the tumor diminishes or is reduced in size.
• the term also includes reduction in the number of metastasis, reduction in the number of new metastasis formed, slowing of the progression of cancer from one stage to the other and a decrease in the angiogenesis induced by the cancer. In one embodiment, the tumor is totally eliminated.
• this term is lengthening of the survival period of the subject undergoing treatment, lengthening the time of diseases progression, tumor regression, and the like. This term also encompasses prevention for prophylactic situations or for those individuals who are susceptible to contracting a tumor.
• the administration of the compounds of the present invention will reduce the likelihood of the individual contracting the disease. In one embodiment, the individual to whom the compound is administered does not contract the disease.
• treating may include directly affecting or curing, suppressing, inhibiting, preventing, reducing an incidence, reducing the severity of, delaying the onset of, reducing symptoms associated with the disease, disorder or condition, or a combination thereof.
• “treating” refers, inter alia, to delaying progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to alternative therapeutics, or a combination thereof.
• treating refers to reducing the pathogenesis of, ameliorating the symptoms of, ameliorating the secondary symptoms of, or prolonging the latency to a relapse of a cancer in a subject.
• “preventing” refers, inter alia, to delaying the onset of symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, or a combination thereof.
• “suppressing” or“inhibiting” refers inter alia to reducing the severity of symptoms, reducing the severity of an acute episode, reducing the number of symptoms, reducing the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, or a combination thereof.
• a subject as described herein has a pre-cancerous condition.
• a subject as described herein has a benign hyperproliferative disorder.
• a subject has cancer.
• pre-cancer or“pre-malignant” as used herein interchangeably refers to diseases, syndromes or other conditions associated with an increased risk of cancer.
• Pre-cancer conditions in the context of the present invention include, but are not limited to: breast calcifications, vaginal intra-epithelial neoplasia, Barrett's esophagus, atrophic gastritis, dyskeratosis congenital, sideropenic dysphagia, lichen planus, oral sibmucous fibrosis, actinic keratosis, solar elastosis, cervical desplasia, leukoplakia and erythroplakia, or other tumor as described herein..
• the term "benign hyperproliferative disorder” as used herein refers to a condition in which there is an abnormal growth and differentiation of cells and an increase in the amount of organic tissue that results from cell proliferation.
• the benign hyperproliferative disorder may be attributed to lack of response or inappropriate response to regulating factors, or alternatively to dysfunctional regulating factors.
• Non-limiting example of benign hyperproliferative disorder are psoriasis and benign prostatic hyperplasia (BPH).
• the subject has a lymphoma.
• lymphomas develop in the glands or nodes of the lymphatic system, a network of vessels, nodes, and organs (in one embodiment, the spleen, tonsils, and thymus) that purify bodily fluids and produce lymphocytes, which, in one embodiment, comprise infection-fighting white blood cells.
• lymphomas are "solid cancers.”
• a lymphoma may occur in a specific organ such as the stomach, breast or brain. In one embodiment such a lymphoma is an extranodal lymphoma.
• a subject as described herein comprises a Mixed Type cancer.
• a mixed type cancer comprises several types of cells.
• the type components may be within one category or from different categories.
• a Mixed Type cancer comprises adenosquamous carcinoma, mixed mesodermal tumor, carcinosarcoma, teratocarcinoma, or a combination thereof.
• cancer includes the above categories of carcinoma, sarcoma, myeloma, leukemia, lymphoma and mixed type tumors.
• cancer includes: lymphoproliferative disorders, breast cancer, ovarian cancer, prostate cancer, cervical cancer, endometrial cancer, lung cancer, bone cancer, liver cancer, stomach cancer, bladder cancer, colon cancer, colorectal cancer, pancreatic cancer, cancer of the thyroid, head and neck cancer, cancer of the central nervous system, brain cancer, cancer of the peripheral nervous system, skin cancer, kidney cancer, as well as metastases of all the above.
• the term may refer to: hepatocellular carcinoma, hematoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, invasive ductal carcinoma, papillary adenocarcinoma, melanoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma (well differentiated, moderately differentiated, poorly differentiated or undifferentiated), renal cell carcinoma, hypernephroma, hypernephroid adenocarcinoma, bile duct carcinoma, choriocar
• the cancer is an adenocarcinoma of the stomach or gastroesophageal junction, Dermatofibrosarcoma protuberans, Endocrine/neuroendocrine tumors, Gastrointestinal stromal tumor, Giant cell tumor of the bone, Kaposi sarcoma, Myelodysplastic/myeloproliferative disorders, Ovarian epithelial/fallopian tube/primary peritoneal cancers, Soft tissue sarcoma, Systemic mastocytosis, Germ cell tumor, or a combination thereof.
• the subject having cancer or a tumor has been treated with surgery, chemotherapy, radiation therapy, a targeted therapy, including therapies that are intended to boost immune system responses against cancer, or a combination thereof.
• the tumor is a solid tumor.
• the solid tumor is a colon carcinoma, prostate cancer, breast cancer, lung cancer, skin cancer, liver cancer, bone cancer, ovary cancer, pancreas cancer, brain cancer, head and neck cancer or other solid tumor.
• the cancer, non-cancerous tumor, or other lesion is in a tissue of the breast, prostate, lung, colon, stomach, pancreas, ovary, brain, skin, bone, fat, lymph, gastrointestinal tract, liver, or soft tissue.
• the tumor is in a tissue that comprises gastrointestinal (GI) tract tissue.
• the GI tract tissue comprises tissue of the anus, rectum, colon, esophagus, stomach, mouth, pharynx, small intestine, liver, pancreas, or biliary tract.
• the cancer is a hematopoietic cancer, a neuroblastoma, or a malignant glioma.
• the tumor or lesion is, without limitation, an adenoma, a hemangioma, a cherry angioma, a lipoma, a lipoblastoma, a hibernoma, a fibroma, a meningioma, a myoma, a leiomeyoma, a rhabdomyoma, a nevi (mole), a neuroma, a neurofibroma, schwannoma, an osteochondroma, a papilloma, seborrheic keratoses, acrochordon, sebaceous hyperplasia, a dermatofibroma, an angiolipoma, a cyst, an epidermal inclusion cyst, a milium, a soft tissue lesion, or a granuloma.
• an adenoma a hemangioma, a cherry angioma, a lipoma,
• any of the methods of the present invention may further comprise the step of contacting one or more cells of said subject with an anti-cancer treatment, or otherwise include a combination treatment or therapy.
• the anti-cancer treatment is radiotherapy.
• the anti-cancer treatment is an anti-cancer drug.
• the anti-cancer drug is a chemotherapeutic.
• the chemotherapeutic comprises 5-fluorouracil, Bleomycin, capecitabine, cisplatin, Cyclophosphamide, dacarbazine, Doxorubicin, Epirubicin, etoposide, folinic acid, Methotrexate, Mustine, oxaliplatin, prednisolone, procarbazine, vinblastine, vincristine, or a combination thereof.
• the present invention provides a method of treating, inhibiting, or suppressing a cancer or tumor in a subject comprising contacting one or more cells of said subject with a tumor reducing composition as described herein and a targeted therapy.
• the present invention provides methods of treating cancer comprising administering a composition as described herein in combination with one or more targeted therapies.
• an immunotherapeutic compound is targeted to particular molecules expressed abnormally by cancer cells.
• the targeted therapy comprises a hormone therapy, signal transduction inhibitor, gene expression modulator, apoptosis inducer, angiogenesis inhibitor, immunotherapy, or toxin delivery molecules.
• the targeted therapy utilizes small molecules.
• the targeted therapy utilizes antibodies, which, in one embodiment, are monoclonal antibodies.
• the immunotherapeutic compound comprises abiraterone acetate (Zytiga®), ado-trastuzumab emtansine (Kadcyla®), afatinib dimaleate (Gilotrif®), alectinib (Alecensa®), alemtuzumab (Campath®), Alitretinoin (Panretin®), anastrozole (Arimidex®), Atezolizumab (TecentriqTM), axitinib (Inlyta®), belinostat (Beleodaq®), Bevacizumab (Avastin®), bexarotene (Targretin®), blinatumomab (Blincyto®), bortezomib (Velcade®), bosutinib (Bosulif®), hrentuximah vedotin (Adcetris
• methods of the present invention further comprise the step of contacting one or more cells of the subject with an immunotherapeutic compound.
• an immunotherapy as described herein is a monoclonal antibody that recognizes specific molecules on the surface of cancer cells.
• binding of the monoclonal antibody to the target molecule results in the immune destruction of cells that express that target molecule.
• the antibody binds to certain immune cells to enhance their actions on cancer cells.
• the immunotherapeutic compound comprises imatinib or trastuzumab.
• the immunotherapeutic compound comprises a checkpoint inhibitor.
• the checkpoint inhibitor comprises a Programmed cell Death protein l(PDl) inhibitor or a Programmed cell Death Ligand 1 (PD-L1) inhibitor.
• the PD-l or PD-L1 inhibitor is an antibody.
• the antibody comprises Nivolumab, Pembrolizumab, Pidilizumab, Avelumab, BMS 936559, or MPDL3280A.
• the immunotherapeutic compound comprises chimeric antigen receptor T cells (CAR T-cells).
• the experimental formulation was comprised of:
• mice were weighed and intratumorally injected with 1 xBfTO or the experimental
• the dosing volume of 1 xBfTO or experimental formulation was at 50 ul each tumor for first week, lOOul for each tumor for 2nd week, 200ul per tumor for the rest of dosing.
• mice Tumor volume and body weight of mice were measured twice a week until the

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pain & Pain Management (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=75267393

Family Applications (1)

Country Status (11)

Cited By (3)

Citations (4)

Family Cites Families (2)

• 2019
  • 2019-07-02 CN CN201980054337.1A patent/CN112584841A/zh active Pending
  • 2019-07-02 EA EA202190201A patent/EA202190201A1/ru unknown
  • 2019-07-02 JP JP2021500520A patent/JP2021530482A/ja not_active Withdrawn
  • 2019-07-02 BR BR112021000279A patent/BR112021000279A8/pt not_active Application Discontinuation
  • 2019-07-02 EP EP19841949.1A patent/EP3820482A4/de not_active Withdrawn
  • 2019-07-02 KR KR1020217003523A patent/KR20220098082A/ko active Search and Examination
  • 2019-07-02 AU AU2019309757A patent/AU2019309757A1/en not_active Abandoned
  • 2019-07-02 CA CA3105717A patent/CA3105717A1/en active Pending
  • 2019-07-02 WO PCT/US2019/040264 patent/WO2020023191A1/en unknown
• 2021
  • 2021-01-06 PH PH12021550033A patent/PH12021550033A1/en unknown
  • 2021-01-07 IL IL280000A patent/IL280000A/en unknown

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events